Case study

INDRAMEDCO

INDRAPRASTHA MEDICAL CORP

Mixed signals1y model +8.6%

Each stock's 10,000-path forecast, rendered as light.

0Score

INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) Stock Analysis & Case Study

Is INDRAMEDCO a good buy? The data-driven verdict.

on the numbers it mixed signals, a Downstox Snapshot Score of 45/100.

On the numbers, INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) mixed signals, a Downstox Snapshot Score of 45/100, weighing a 57% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 20272031.

Last updated . Data snapshot for research, not investment advice.

INDRAMEDCO share price target 2027, 2028, 2029, 2030, 2031, a probability view

Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of INDRAMEDCO history (21%/yr drift, 50%/yr volatility).

YearLow (P10)Median target (P50)High (P90)Upside vs today
INDRAMEDCO 2027₹220₹416₹781+9%
INDRAMEDCO 2028₹184₹456₹1,111+19%
INDRAMEDCO 2029₹162₹492₹1,482+28%
INDRAMEDCO 2030₹154₹547₹1,910+43%
INDRAMEDCO 2031₹141₹587₹2,423+53%

Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.

What is the probability INDRAMEDCO goes up, or doubles?

57%
Higher in 1 year
Modelled chance the price is above today in 12 months
65%
Higher in 5 years
Modelled chance the price is above today in 5 years
41%
Doubles in 5 years
Modelled chance of reaching ₹766 within 5 years

The bull case for INDRAMEDCO

  • INDRAPRASTHA MEDICAL CORP is part of the NSE universe with live, tracked fundamentals on Downstox.
  • Upside scenario: the model's optimistic (P90) 3-year path reaches ₹1,482.

The bear case & risks

  • High historical volatility (50%/yr) means a wide, bumpy range of outcomes, size positions accordingly.
  • Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹162.

INDRAMEDCO volatility & expected range, how bumpy is the ride?

Over the last 2.0 years INDRAMEDCO compounded at 21%/year with annualized volatility of 50%. That volatility implies a 1-year 80% range of ₹220₹781, the honest backbone behind any single price target.

INDRAMEDCO price forecast, the full 60-month probability fan

Spot Price · Today
₹0
Based on 2.0 years of daily NSE data ·0.0% annualised volatility
5-yr median forecast
₹0
P(price ↑ in 5y)
0%
1-Year Forecast
2027
₹0
Median (P50)
8.6%
80% range₹220–₹781
P(price ↑)57%
P(price 2×)11%
3-Year Forecast
2029
₹0
Median (P50)
28.4%
80% range₹162–₹1,482
P(price ↑)62%
P(price 2×)31%
5-Year Forecast
2031
₹0
Median (P50)
53.3%
80% range₹141–₹2,423
P(price ↑)65%
P(price 2×)41%

INDRAMEDCO price probability fan

Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.

Probability Fan
INDRAMEDCO simulated paths · 60 months · 10,000 trials
P10–P90 (80%)P25–P75 (50%)Median (P50)

Probability of key outcomes

What are the odds INDRAMEDCO hits common targets within the simulated horizon?

0%
P(↑ 1Y)
Above today's price in 1 year
0%
P(↑ 5Y)
Above today's price in 5 years
0%
P(2×)
Doubles within 5 years
0%
P(↓)
Falls below today in 5 years

Full multi-horizon detail on the INDRAMEDCO price target & forecast page.

INDRAMEDCO MTF margin & leverage, Upstox, Zerodha, Groww, Dhan

Margin Trading Facility lets you buy INDRAMEDCO with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):

BrokerMargin requiredApprox. leverage
UpstoxCHEAPEST36.4%2.7×
ZerodhaCHEAPEST36.4%2.7×
DhanCHEAPEST36.4%2.7×

Compare every broker on the INDRAMEDCO MTF page.

INDRAMEDCO vs peers,sector comparison

StockP/EDiv yieldMarket cap
INDRAMEDCO (this stock)
RELIANCE23.1×0.45%₹17.95L Cr
TCS14.7×3.01%₹7.69L Cr
HDFCBANK15.9×1.65%₹12.11L Cr
INFY14.4×4.51%₹4.32L Cr
ICICIBANK17.9×0.81%₹9.70L Cr
SBIN11.5×1.67%₹9.61L Cr

About INDRAPRASTHA MEDICAL CORP: sector, index & market-cap context

INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) is an NSE-listed company.

How the INDRAMEDCO Snapshot Score & forecast are built

The Downstox Snapshot Score is a transparent, rules-based read of INDRAPRASTHA MEDICAL CORP's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.

This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.

INDRAMEDCO analysis, FAQs

Is INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) a good buy?

On the numbers, INDRAPRASTHA MEDICAL CORP (INDRAMEDCO) mixed signals, a Downstox Snapshot Score of 45/100, weighing a 57% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.

Is INDRAMEDCO overvalued or undervalued?

Valuation ratios for INDRAMEDCO are tracked live on Downstox.

What is the INDRAMEDCO share price target for 2031?

INDRAMEDCO's probability-weighted 2031 median target is ₹587, with an 80% range of ₹141₹2,423 (10,000-path Monte-Carlo).

What is the probability INDRAMEDCO doubles in 5 years?

The modelled probability of INDRAMEDCO reaching ₹766 (2×) within 5 years is 41%.

What is the bull case for INDRAMEDCO?

INDRAPRASTHA MEDICAL CORP is part of the NSE universe with live, tracked fundamentals on Downstox.

What are the risks in INDRAMEDCO?

High historical volatility (50%/yr) means a wide, bumpy range of outcomes, size positions accordingly.

More on INDRAMEDCO